Select Your Region
Global
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
- Follicular Lymphoma
Trial Status:
Active, not recruiting
This trial runs in
Cities
- Alessandria
- Avellino
- Aviano
- Bari
- Barletta
- Bergamo
- Bologna
- Cagliari
- Campania
- Caserta
- Catania
- Firenze
- Lazio
- Lecce
- Milano
- Modena
- Napoli
- Nuoro
- Padova
- Palermo
- Pavia
- Perugia
- Pescara
- Pisa
- Prato
- Reggio Calabria
- Reggio Emilia
- Roma
- San Giovanni Rotondo
- Siena
- Terni
- Torino
- Torrette
- Treviso
- Tricase
- Udine
- Varese
- Verona
Trial Identifier:
NCT04034056 ML41215
Trial Summary
To evaluate the effectiveness and safety of obinutuzumab in clinical routine in 1L FL measured by the % of relapse within 24 months from start of therapy.
Hoffmann-La Roche
Sponsor
NCT04034056 , ML41215
Trial Identifier
Obinutuzumab
Treatments
Follicular Lymphoma
Condition
Official Title
A Non-Interventional, Retrospective And Prospective, Multicenter, Single Arm Study Evaluating The Effectiveness And Safety Of Obinutuzumab In Patients With Previously Untreated Advanced Follicular Lymphoma
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Signed Informed consent according to local regulations, after performing at least 2 cycles of induction treatment with Obinutuzumab and chemotherapy, within 1 year from beginning of treatment
Exclusion Criteria
- Any contraindications to Obinutuzumab therapy according to local label for specific indication;
- Concomitant participation in an interventional clinical study;
- Participants not receiving treatment for untreated follicular lymphoma with Obinutuzumab according to standard of care and in line with local labeling.
For the latest version of this information please go to www.forpatients.roche.com